Karen Cromie

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 7.6

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Merebeke, BE (2019)
Merelbeke, BE (2013 - 2022)
Zwijnaarde, BE (2020 - 2024)

Company Filing History:

Boehringer Ingelheim International Gmbh

Years Active: 2013-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285493 - Polypeptides antagonizing Wnt signaling in tumor cells (2025-04-29),

2. 11952418 - Biparatopic polypeptides antagonizing Wnt signaling in tumor cells (2024-04-09),

3. 11466089 - Chemokine receptor binding polypeptides (2022-10-11),

4. 11033636 - Polypeptides antagonizing Wnt signaling in tumor cells (2021-06-15),

5. 10597449 - Biparatopic polypeptides antagonizing Wnt signaling in tumor cells (2020-03-24),

6. 10174118 - Nucleic acids encoding chemokine receptor binding polypeptides (2019-01-08),

7. 9688763 - Chemokine receptor binding polypeptides (2017-06-27),

8. 9328174 - Chemokine receptor binding polypeptides (2016-05-03),

9. 9127067 - Methods of treatment using chemokine receptor binding polypeptides (2015-09-08),

10. 9120855 - Biologic compounds directed against death receptor 5 (2015-09-01),

11. 8591896 - Chemokine receptor binding polypeptides (2013-11-26),

Title: Karen Cromie: Innovator in Cancer Treatment

Introduction

Karen Cromie is a notable inventor based in Merelbeke, Belgium, recognized for her significant contributions to the field of cancer research. With a total of 11 patents to her name, she has made remarkable strides in developing innovative treatments targeting tumor cells.

Latest Patents

Among her latest patents, the invention titled "Polypeptides antagonizing Wnt signaling in tumor cells" stands out. This invention provides LRP5-binding polypeptides, specifically LRP5-binding immunoglobulin single variable domain constructs that can inhibit Wnt signaling pathways. The invention also details specific sequences of such polypeptides, methods of their production, and methods of using them, including treatment methods for diseases such as cancer. Another significant patent is "Biparatopic polypeptides antagonizing Wnt signaling in tumor cells." This invention introduces novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, particularly novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs that can inhibit Wnt signaling pathways. Similar to her previous patent, this invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them for treating diseases like cancer.

Career Highlights

Throughout her career, Karen Cromie has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Boehringer Ingelheim International GmbH. Her work in these organizations has significantly contributed to advancements in medical research and treatment options.

Collaborations

Karen has collaborated with esteemed colleagues such as Bruno Dombrecht and Marie-Ange Buyse, further enhancing her research and innovation efforts.

Conclusion

Karen Cromie's work exemplifies the impact of innovative thinking in the field of cancer treatment. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.